

Unlocking the Protein World

ProteoWise is founded by a seasoned team of scientists from the Strittmatter Lab at Yale University with a history of innovations, from founding two new centers at Yale to the biotech company ReNetx.

We asked, "What will deliver the next wave in biotech?" High-throughput sequencing of DNA brought about the genomic revolution. But there's been no similar advancement in proteomic technology, even though there's more valuable information locked up in the world of proteins.


The gold standard for protein analysis remains 40-year old tech called "western blot". It's slow, cumbersome, expensive and only analyzes one or two proteins per sample. Every biology lab in the world uses it and everyone hates it.

We hate it too. That's why we invented a proteomic technology that's **50x faster**, **50x smaller**, **10x cheaper and gives 100x more data** per sample. It will enable researchers to finally move beyond western blot and into easy, high-throughput bench-top proteomics.


This will disrupt the \$1B western blot/multiplex proteomics market and accelerate biotechnological research world-wide.

The key to our tech is a nanoscale material we invented that's being patented. We call it 3-Dimensional Nanoscale Protein Capture, or **3D-NPC**.

By binding proteins covalently in a rigid nanoporous structure, 3D-NPC can be rapidly and repeatedly addressed with antibody probes. This solves all the problems of western blot while providing molecular weight and identity information that researchers need.



Strong Competitive Advantage



ProteoWise's technology provides a unique combination of high information content, high throughput, and low cost - all while simplifying the western blot dramatically. This combination is what's driving the genomic revolution and is needed for proteomics.

ProteoWise has established a rapid path to engineering and commercializing an instrument that will re-make biotech and biomedicine. We are seeking series A financing to reach pre-production β -model, in 3 milestone-driven tranches. Erik Gunther, CEO erik.gunther@yale.edu